These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 28161119

  • 21. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
    Ringe JD, Dorst A, Faber H, Ibach K, Preuss J.
    Rheumatology (Oxford); 2003 Jun; 42(6):743-9. PubMed ID: 12730532
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
    Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD.
    Ann Rheum Dis; 2006 May; 65(5):654-61. PubMed ID: 16339289
    [Abstract] [Full Text] [Related]

  • 24. Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial.
    Chapurlat RD, Laroche M, Thomas T, Rouanet S, Delmas PD, de Vernejoul MC.
    Osteoporos Int; 2013 Jan; 24(1):311-20. PubMed ID: 22402673
    [Abstract] [Full Text] [Related]

  • 25. Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial.
    Livi L, Scotti V, Desideri I, Saieva C, Cecchini S, Francolini G, Becherini C, Delli Paoli C, Visani L, Salvestrini V, De Feo ML, Nori J, Bernini M, Sanchez L, Orzalesi L, Bianchi S, Meattini I.
    Eur J Cancer; 2019 Feb; 108():100-110. PubMed ID: 30648627
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR.
    J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
    [Abstract] [Full Text] [Related]

  • 27. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
    Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F.
    Osteoporos Int; 2003 Oct; 14(10):801-7. PubMed ID: 14610641
    [Abstract] [Full Text] [Related]

  • 28. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP.
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study.
    Nakano T, Yamamoto M, Hashimoto J, Tobinai M, Yoshida S, Nakamura T.
    J Bone Miner Metab; 2016 Nov; 34(6):678-684. PubMed ID: 26462480
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
    Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, Coutant K, Schimmer RC, Delmas PD.
    Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY.
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [Abstract] [Full Text] [Related]

  • 39. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
    Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, Nakano T, Mizunuma H, MOVEST Study Group.
    Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561
    [Abstract] [Full Text] [Related]

  • 40. Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.
    Klaus J, Reinshagen M, Herdt K, Schröter C, Adler G, von Boyen GB, von Tirpitz C.
    World J Gastroenterol; 2011 Jan 21; 17(3):334-42. PubMed ID: 21253392
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.